A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Trial Profile

A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2016 Status changed from active, no longer recruiting to discontinued, according toan abstract presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results (n=4) analysing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
    • 08 Apr 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top